莱美药业(300006) - 2022 Q3 - 季度财报

Financial Performance - The company's revenue for Q3 2022 was ¥264,421,982.22, a decrease of 5.47% compared to the same period last year, and a total revenue of ¥670,853,551.45 for the year-to-date, down 24.77%[4] - The net profit attributable to shareholders for Q3 2022 was ¥11,698,716.60, while the year-to-date net profit was -¥37,373,010.95, reflecting a significant decline of 287.15%[4] - The basic earnings per share for Q3 2022 was ¥0.0111, compared to -¥0.0354 for the same period last year, indicating a decrease of 272.68%[4] - Total operating revenue for the third quarter was ¥670,853,551.45, a decrease of 24.7% compared to ¥891,700,644.80 in the same period last year[23] - The company reported an operating loss of ¥66,999,884.21, compared to an operating profit of ¥25,717,051.29 in the previous year[23] - Net profit for the period was a loss of ¥46,070,929.86, contrasting with a profit of ¥25,413,513.35 in the same quarter last year[23] - The net profit for the third quarter of 2022 was -44,728,469.91 CNY, compared to a net profit of 16,959,509.20 CNY in the same period last year, indicating a significant decline[24] - The company reported a basic and diluted earnings per share of -0.0354 CNY, compared to 0.0205 CNY in the same period last year[24] Assets and Liabilities - The company's total assets at the end of Q3 2022 were ¥3,037,979,049.22, an increase of 3.80% from the end of the previous year[4] - Total assets reached ¥3,037,979,049.22, up from ¥2,926,773,933.76, indicating a growth of 3.8%[21] - The company’s total liabilities increased to ¥833,343,198.44, compared to ¥714,647,217.06, reflecting a rise of 16.6%[21] - The company’s total current assets increased to ¥1,795,368,277.29 from ¥1,726,995,266.10, a growth of 3.9%[20] Cash Flow - Cash flow from operating activities for the year-to-date was -¥26,539,836.25, a decline of 140.08% compared to the previous year[11] - The operating cash flow for the period was -26,539,836.25 CNY, a decrease from 66,213,762.66 CNY in the previous year, reflecting a negative cash flow situation[27] - The total cash inflow from operating activities was 1,071,511,372.34 CNY, down from 1,266,731,649.78 CNY year-over-year, indicating a decrease of about 15.4%[27] - The total cash outflow from operating activities was 1,098,051,208.59 CNY, a decrease from 1,200,517,887.12 CNY in the previous year[27] - The company reported a cash and cash equivalents balance of 686,921,451.70 CNY at the end of the period, an increase from 617,860,422.49 CNY at the end of the previous year[28] - Cash and cash equivalents increased to ¥738,378,951.70 from ¥559,430,726.55, representing a growth of 32.0%[20] - The net cash flow from financing activities was 177,280,866.53 CNY, compared to 135,025,164.38 CNY in the same period last year, showing an increase of approximately 31.4%[28] - The company received 351,999,999.00 CNY in borrowings during the period, a significant increase from 91,000,000.00 CNY in the previous year[28] Investments and Acquisitions - The company reported a significant increase in long-term equity investments by 45.80%, totaling ¥136,649,586.16, due to increased external investments[8] - Long-term equity investments rose to ¥136,649,586.16 from ¥93,724,606.83, marking an increase of 46.0%[20] - The company acquired all tangible and intangible assets related to the injection of Triptorelin Acetate from Hainan Shuangcheng Pharmaceutical Co., Ltd. for RMB 28.8 million[15] - The company is actively involved in strategic partnerships and acquisitions to enhance its market position and product portfolio[15] Regulatory Approvals - The company received drug registration certificates for two specifications of Esomeprazole Magnesium Enteric-coated Capsules (20mg and 40mg) from the National Medical Products Administration[16] - The company received approval for two specifications of Tranexamic Acid Injection (5ml: 0.25g and 5ml: 0.5g) after passing the consistency evaluation of generic drug quality and efficacy[16] - The company received approval for the injection of Fludarabine Phosphate (50mg) after passing the consistency evaluation of generic drug quality and efficacy[17] - The company has received various approvals for its pharmaceutical products, indicating ongoing expansion in its product offerings[16][17] Legal Matters - The company recognized a net loss of RMB 35,377,357.50 based on a first-instance judgment regarding a lawsuit related to the exclusive sales agency rights of Tadalafil[17] - The second-instance judgment of the lawsuit resulted in an impact of RMB 21 million on the company's non-operating income for the current period[17] Research and Development - Research and development expenses for the quarter were ¥54,423,054.23, slightly up from ¥51,915,525.42, indicating a focus on innovation[23] Shareholder Information - The company has a total of 128,700,000 shares held by Qiu Yu, representing a significant portion of its equity[19]